Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Macrophage-targeted Therapy Unlocks Antitumoral Crosstalk Between IFN휸-secreting Lymphocytes and IL12-producing Dendritic Cells

ABSTRACT: Macrophage-targeted Therapy Unlocks Antitumoral Crosstalk Between IFN휸-secreting Lymphocytes and IL12-producing Dendritic Cells

PROVIDER: PRJNA679323 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13082456_1.fastq.gz	Fastqsanger.gz
	SRR13082456_2.fastq.gz	Fastqsanger.gz
	SRR13082457.fastq.gz	Fastqsanger.gz
	SRR13082458_1.fastq.gz	Fastqsanger.gz
	SRR13082458_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

Macrophage-targeted Therapy Unlocks Antitumoral Crosstalk Between IFN -secreting Lymphocytes and IL12-producing Dendritic Cells

Project description:Macrophages often abound within tumors, express colony-stimulating factor 1 receptor (CSF1R), and are linked to adverse patient survival. Drugs blocking CSF1R signaling have been used to suppress tumor-promoting macrophage responses; however, their mechanisms of action remain incompletely understood. Here, we assessed the lung tumor immune microenvironment in mice treated with BLZ945, a prototypical small-molecule CSF1R inhibitor, using single-cell RNA sequencing and mechanistic validation approaches. We showed that tumor control was not caused by CSF1R+ cell depletion; instead, CSF1R targeting reshaped the CSF1R+ cell landscape, which unlocked crosstalk between antitumoral CSF1R- cells. These cells included IFN -producing natural killer and T cells, and an IL12-producing dendritic cell subset, denoted as DC3, which were all necessary for CSF1R inhibitor–mediated lung tumor control. These data indicate that CSF1R targeting can activate a cardinal crosstalk between cells that are not macrophages and that are essential to mediate the effects of T cell–targeted immunotherapies and promote antitumor immunity.

2021-12-01 | GSE161771 | GEO

Macrophage-Targeted Therapy Unlocks Antitumoral Cross-talk between IFNγ-Secreting Lymphocytes and IL12-Producing Dendritic Cells.

Project description:Macrophages often abound within tumors, express colony-stimulating factor 1 receptor (CSF1R), and are linked to adverse patient survival. Drugs blocking CSF1R signaling have been used to suppress tumor-promoting macrophage responses; however, their mechanisms of action remain incompletely understood. Here, we assessed the lung tumor immune microenvironment in mice treated with BLZ945, a prototypical small-molecule CSF1R inhibitor, using single-cell RNA sequencing and mechanistic validation approaches. We showed that tumor control was not caused by CSF1R+ cell depletion; instead, CSF1R targeting reshaped the CSF1R+ cell landscape, which unlocked cross-talk between antitumoral CSF1R- cells. These cells included IFNγ-producing natural killer and T cells, and an IL12-producing dendritic cell subset, denoted as DC3, which were all necessary for CSF1R inhibitor-mediated lung tumor control. These data indicate that CSF1R targeting can activate a cardinal cross-talk between cells that are not macrophages and that are essential to mediate the effects of T cell-targeted immunotherapies and promote antitumor immunity.See related Spotlight by Burrello and de Visser, p. 4.

| S-EPMC10132467 | biostudies-literature

Aspirin antitumoral effect on pituitary adenoma

Project description:Aspirin antitumoral effect on pituitary adenoma

| PRJNA837778 | ENA

Human peripheral IL-10-secreting vs non- IL-10-secreting B cells

Project description:Transcriptional profiling of human peripheral B cell subsets sorted by flow cytometry based on the secretion of IL-10 in response to CpG2006 stimulation. Goal was to identify molecular markers to distinguish IL-10-producing B cells form non-IL-10-producing B cells. Two-condition experiment, non-IL-10-secreting B cells vs. IL-10-secreting B cells. Healthy donors. Biological replicates: 6

2013-03-04 | E-GEOD-35002 | biostudies-arrayexpress

Aspirin antitumoral effect on pituitary adenoma

Project description:Aspirin, is a commonly used non-steroidal anti-inflammatory drug with antipyretic, analgesic, anti-inflammatory, and anti-thrombotic effect. Its antitumoral effect was also demonstrated in several cancer types. In this study our aim was to investigate the genomic effects of ASA in pituitary adenomas using high-throughput profiling approaches and validate our findings by targeted methodologies, using in vitro functional assays. Whole transcriptome profile of RC4-B/C and GH3 pituitary cell lines upon Aspirin treatment was investigated.

2022-06-19 | GSE202934 | GEO

Single cell RNA sequencing of the lung pre-metastatic niche in a syngeneic mouse model of rhabdomyosarcoma

Project description:C57BL/6 mice were injected orthotopically with M3-9-M ffluc-mCherry rhabdomyosarcoma tumor cells in the gastrocnemius muscle of the leg. Mice were treated with 8E6 IL12-secreting genetically engineered myeloid cells (IL12-GEMys) on day 12 post tumor inoculation. Lungs were harvested 3 days post IL12-GEMy treatment, 15 days post primary tumor inoculation. 3' single cell RNA-Seq was performed on isolated cells.

2021-03-29 | GSE168297 | GEO

Epigenetic crosstalk

Project description:Epigenetic crosstalk

| PRJNA707004 | ENA

LSD1/GR crosstalk

Project description:LSD1/GR crosstalk

| PRJNA961742 | ENA

Growth Hormone (GH) -secreting Pituitary Adenoma

Project description:We profiled the somatic landscape of 21 growth hormone (GH) -secreting pituitary adenomas using somatic copy-number alteration (SCNA), whole-genome sequencing (WGS), bisulfate sequencing, and transcriptome approaches. See details in Valimaki et al. Genetic and epigenetic characterization of growth hormone (GH) - secreting pituitary tumors. Manuscript in preparation, 2019.

| EGAS00001003488 | EGA

Targeting BMI-1 to deplete antibody-secreting cells in autoimmunity

Project description:We measured genes expression differences in antibody secreting cells from LynKO mice in following treatment with a BMI-1 inhibitor (PTC-028) or a vehicle control. BMI-1 inhibition lead to a reduction in antibody secreting cells in LynKO mice and in humans donors. We performed RNA sequencing to understand the impact of BMI-1 inhibition on antibody secreting cells in LynKO mice.

2023-10-05 | GSE239515 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data